Sugi Predict

Sugi Predict / Compounds / SCHEMBL3409068

SCHEMBL3409068

SCHEMBL3409068

COCCNS(=O)(=O)c1cc(-c2cnc(N)c(C(=O)c3cccnc3)n2)ccc1Cl

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 16/20 0.70
▸ CCNE2 O96020 1/20 0.59
▸ CCNE1 P24864 1/20 0.59
▸ CDK2 P24941 1/20 0.59
▸ GSK3B P49841 1/20 0.59
▸ PIK3CA P42336 15/20 0.55
▸ PIK3CB P42338 15/20 0.55
▸ PIK3CG P48736 15/20 0.55
▸ EGFR P00533 2/20 0.48
▸ RAF1 P04049 2/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ MTOR P42345 2/20 0.48
▸ MAP2K1 Q02750 2/20 0.48
▸ CYP2C8 P10632 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ CDK5 Q00535 1/20 0.48
▸ CDK5R1 Q15078 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3410562 0.88 CCNE2 (0.56) PIK3CDCCNE2CCNE1CDK2GSK3B
SCHEMBL3409202 0.86 CCNE2 (0.63) PIK3CDCCNE2CCNE1CDK2GSK3B
SCHEMBL3408387 0.82 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGCDK5
SCHEMBL11969468 0.82 PIK3CD (0.75) PIK3CDPIK3CAPIK3CBPIK3CGEGFR
SCHEMBL3410302 0.82 CCNE2 (0.53) PIK3CDCCNE2CCNE1CDK2GSK3B
SCHEMBL3404697 0.80 PIK3CD (0.72) PIK3CDPIK3CAPIK3CBPIK3CGEGFR
SCHEMBL11992024 0.80 PIK3CD (0.72) PIK3CDPIK3CAPIK3CBPIK3CGEGFR
SCHEMBL21369133 0.80 PIK3CD (0.71) PIK3CDPIK3CAPIK3CBPIK3CGEGFR
SCHEMBL3411415 0.79 PIK3CD (0.68) PIK3CDPIK3CAPIK3CBPIK3CGCDK5
SCHEMBL3402725 0.78 PIK3CD (0.65) PIK3CDCCNE2CCNE1CDK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268834-B2 Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme NOVARTIS AG (CH) 2012-09-18 — — US claimed
EP-2257529-A2 PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K Novartis AG (CH) 2010-12-08 — — EP claimed
WO-2009115517-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-24 — — WO claimed
US-20090239847-A1 Organic compounds NOVARTIS AG (CH) 2009-09-24 — — US claimed
EP-3134396-B1 AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2019-09-18 — — EP disclosed
US-10004732-B2 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors NOVARTIS AG (CH) 2018-06-26 — — US disclosed
US-10004732-B2 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors NOVARTIS AG (CH) 2018-06-26 — — US disclosed
US-20170042889-A1 AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2017-02-16 — — US disclosed
US-20170042889-A1 AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2017-02-16 — — US disclosed
US-20170037032-A1 AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2017-02-09 — — US disclosed
US-20170037032-A1 AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2017-02-09 — — US disclosed
US-8846687-B2 Pyrazine compounds as PI3 kinase inhibitors NOVARTIS AG (CH) 2014-09-30 — — US disclosed
US-20120214800-A1 Organic Compounds NOVARTIS AG (CH) 2012-08-23 — — US disclosed
US-20120214800-A1 Organic Compounds NOVARTIS AG (CH) 2012-08-23 — — US disclosed
EP-2257529-A2 PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K Novartis AG (CH) 2010-12-08 — — EP disclosed
WO-2009115517-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-24 — — WO disclosed
WO-2009115517-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-24 — — WO disclosed
US-20090239847-A1 Organic compounds NOVARTIS AG (CH) 2009-09-24 — — US disclosed
US-20090239847-A1 Organic compounds NOVARTIS AG (CH) 2009-09-24 — — US disclosed
US-20090239847-A1 Organic compounds NOVARTIS AG (CH) 2009-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037032-A1 AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PI4KA, PIP4K2B, PHKG1 PIK3CD 15/4885CCNE2 2657/4885CCNE1 1459/4885
US-20090239847-A1 Organic compounds AR, TRPA1, IL33 PIK3CD 4406/4885CCNE2 2451/4885CCNE1 2616/4885
US-10004732-B2 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors PI4KA, PIP5K1B, PIP4K2B PIK3CD 15/4885CCNE2 2400/4885CCNE1 1310/4885
US-20170042889-A1 AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PI4KA, PIP5K1B, PIP4K2B PIK3CD 15/4885CCNE2 2400/4885CCNE1 1310/4885
US-20120214800-A1 Organic Compounds AR, TRPA1, IL33 PIK3CD 4406/4885CCNE2 2451/4885CCNE1 2616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.